Aethlon Medical to Present at the H.C. Wainwright BioConnect 2021 Conference
Aethlon Medical, Inc. (Nasdaq: AEMD) will present at the virtual H.C. Wainwright BioConnect 2021 Conference from Jan. 11-14, 2021. A webcast of their presentation will be available on-demand starting at 6:00 a.m. EDT on Jan. 11, accessible through their website. The company focuses on addressing unmet needs in viral diseases and cancer with its Hemopurifier device, designated as a Breakthrough Device by the FDA. It aims to combat cancer by depleting tumor-derived exosomes and has received FDA approval for an Early Feasibility Study for COVID-19 treatment.
- None.
- None.
SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, today announced that the company will participate in the virtual H.C. Wainwright BioConnect 2021 Conference to be held Jan. 11-14, 2021.
A webcast of Aethlon Medical's presentation will be available on-demand as of 6:00 a.m. EDT, Monday, Jan. 11, 2021. The webcast can be accessed at https://journey.ct.events/view/438e8db3-76ee-47fc-8af0-3270786018d9 and the investor relations section of Aethlon Medical's website at www.aethlonmedical.com.
About Aethlon and the Hemopurifier®
Aethlon is focused on addressing unmet needs in global health. The Aethlon Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. In cancer, the Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression.
The Hemopurifier® is an FDA designated "Breakthrough Device" related to the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease cancer. Under an Investigational Device Exemption (IDE) application, in October 2019 the FDA approved an Early Feasibility Study (EFS), which is the device equivalent of a Phase 1 clinical trial for a drug or biologic, in a single center, open label trial in 10 to 12 subjects. The study is evaluating the HEMOPURIFIER® for reducing cancer-associated exosomes prior to the administration of standard-of-care pembrolizumab (KEYTRUDA®), which is a first-line therapy for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. The EFS is being conducted at the University of Pittsburgh Medical Center Hillman Cancer Center.
The Hemopurifier also holds a Breakthrough Device designation related to life-threatening viruses that are not addressed with approved therapies. In June 2020, the FDA approved an amendment to the Company's existing open IDE for the Hemopurifier in life threatening viral infections, to allow for the treatment of patients with SARS-CoV-2/COVID-19 infection. This will allow for up to 40 of these patients to be treated under a new Early Feasibility Study protocol at up to 20 clinical sites in the U.S.
Aethlon also owns
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially," "appear" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation, Aethlon Medical, Inc.'s (the Company) ability to enroll patients in the Early Feasibility Studies, the Company's ability to successfully complete the Early Feasibility Studies and achieve the endpoints for the studies, or any future studies with its Hemopurifier or to successfully develop and commercialize the Hemopurifier. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2020, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.
Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Media Contact:
Tony Russo, Ph.D.
Russo Partners, LLC
tony.russo@russopartnersllc.com
212-845-4251
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
212-966-3650
View original content:http://www.prnewswire.com/news-releases/aethlon-medical-to-present-at-the-hc-wainwright-bioconnect-2021-conference-301199514.html
SOURCE Aethlon Medical, Inc.
FAQ
When will Aethlon Medical present at the H.C. Wainwright BioConnect 2021 Conference?
How can I access the Aethlon Medical presentation webcast?
What is the Aethlon Hemopurifier?
What is the significance of the FDA Breakthrough Device designation for the Hemopurifier?
What is the current focus of Aethlon Medical's research?
What studies is Aethlon Medical conducting for COVID-19 treatment?
